Cargando…

A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome

Objective  Amantadine has both anti-glutamatergic and dopaminergic action and may improve restless legs syndrome (RLS). We compared the efficacy and adverse-effect profile of amantadine and ropinirole in RLS. Methods  In this randomized, open-label, 12-week flexible-dose exploratory study, RLS patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhaw, Govind, Gupta, Ravi, Dhamija, Puneet, Kumar, Niraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda. 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325843/
https://www.ncbi.nlm.nih.gov/pubmed/37425973
http://dx.doi.org/10.1055/s-0043-1770810
_version_ 1785069302657843200
author Madhaw, Govind
Gupta, Ravi
Dhamija, Puneet
Kumar, Niraj
author_facet Madhaw, Govind
Gupta, Ravi
Dhamija, Puneet
Kumar, Niraj
author_sort Madhaw, Govind
collection PubMed
description Objective  Amantadine has both anti-glutamatergic and dopaminergic action and may improve restless legs syndrome (RLS). We compared the efficacy and adverse-effect profile of amantadine and ropinirole in RLS. Methods  In this randomized, open-label, 12-week flexible-dose exploratory study, RLS patients with international RLS study group severity scale score (IRLSS) > 10 were randomized to receive either amantadine(100-300mg/day) or ropinirole (0.5-2mg/day). Drug dose was increased until week-6 if IRLSS failed to improve by ≥10% of previous visit score. IRLSS change from baseline at week-12 was the primary outcome. Secondary outcomes included change in RLS-related quality of life (RLS-QOL) and insomnia severity index (ISI), along with clinical-global-impression of change/improvement (CGI-I), and proportion of patients with adverse-effects and resulting discontinuation. Results  Twenty-four patients received amantadine and 22 received ropinirole. Both groups had a significant effect for visit*treatment arm (F (2.19,68.15) =4.35;P = 0.01). With a similar baseline IRLSS, both intention-to-treat (ITT) and per-protocol analyses revealed comparable IRLSS until week-8, with ropinirole appearing superior from week-10 to week-12 (week-12 IRLSS, amantadine vs ropinirole:17.0  ±   5.7 vs 9.0  ±   4.4;P < 0.001). ITT analysis at week-12 showed comparable proportion of responders (≥10% IRLSS reduction) in both groups (P = 0.10). Both drugs improved sleep and QOL, but week-12 scores favoured ropinirole [(ISI:14.4  ±   5.7 vs 9.4  ±   4.5; P = 0.001) ;(RLS-QOL:70.4  ±   17.9 vs 86.5  ±   9.8; P = 0.005)]. CGI-I at week-12 favoured ropinirole (Mann-Whitney U = 35.50, S. E = 23.05;P = 0.01). Four patients in amantadine and two in ropinirole group developed adverse effects, with resulting discontinuation in two patients on amantadine. Conclusions  The present study reports equivalent reduction in RLS symptoms with both amantadine and ropinirole until week-8, with the latter being superior from week-10 onwards. Ropinirole was better tolerated.
format Online
Article
Text
id pubmed-10325843
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Thieme Revinter Publicações Ltda.
record_format MEDLINE/PubMed
spelling pubmed-103258432023-07-07 A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome Madhaw, Govind Gupta, Ravi Dhamija, Puneet Kumar, Niraj Sleep Sci Objective  Amantadine has both anti-glutamatergic and dopaminergic action and may improve restless legs syndrome (RLS). We compared the efficacy and adverse-effect profile of amantadine and ropinirole in RLS. Methods  In this randomized, open-label, 12-week flexible-dose exploratory study, RLS patients with international RLS study group severity scale score (IRLSS) > 10 were randomized to receive either amantadine(100-300mg/day) or ropinirole (0.5-2mg/day). Drug dose was increased until week-6 if IRLSS failed to improve by ≥10% of previous visit score. IRLSS change from baseline at week-12 was the primary outcome. Secondary outcomes included change in RLS-related quality of life (RLS-QOL) and insomnia severity index (ISI), along with clinical-global-impression of change/improvement (CGI-I), and proportion of patients with adverse-effects and resulting discontinuation. Results  Twenty-four patients received amantadine and 22 received ropinirole. Both groups had a significant effect for visit*treatment arm (F (2.19,68.15) =4.35;P = 0.01). With a similar baseline IRLSS, both intention-to-treat (ITT) and per-protocol analyses revealed comparable IRLSS until week-8, with ropinirole appearing superior from week-10 to week-12 (week-12 IRLSS, amantadine vs ropinirole:17.0  ±   5.7 vs 9.0  ±   4.4;P < 0.001). ITT analysis at week-12 showed comparable proportion of responders (≥10% IRLSS reduction) in both groups (P = 0.10). Both drugs improved sleep and QOL, but week-12 scores favoured ropinirole [(ISI:14.4  ±   5.7 vs 9.4  ±   4.5; P = 0.001) ;(RLS-QOL:70.4  ±   17.9 vs 86.5  ±   9.8; P = 0.005)]. CGI-I at week-12 favoured ropinirole (Mann-Whitney U = 35.50, S. E = 23.05;P = 0.01). Four patients in amantadine and two in ropinirole group developed adverse effects, with resulting discontinuation in two patients on amantadine. Conclusions  The present study reports equivalent reduction in RLS symptoms with both amantadine and ropinirole until week-8, with the latter being superior from week-10 onwards. Ropinirole was better tolerated. Thieme Revinter Publicações Ltda. 2023-07-06 /pmc/articles/PMC10325843/ /pubmed/37425973 http://dx.doi.org/10.1055/s-0043-1770810 Text en Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Madhaw, Govind
Gupta, Ravi
Dhamija, Puneet
Kumar, Niraj
A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome
title A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome
title_full A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome
title_fullStr A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome
title_full_unstemmed A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome
title_short A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome
title_sort randomized, open label, exploratory trial comparing efficacy of amantadine and ropinirole in restless legs syndrome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325843/
https://www.ncbi.nlm.nih.gov/pubmed/37425973
http://dx.doi.org/10.1055/s-0043-1770810
work_keys_str_mv AT madhawgovind arandomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome
AT guptaravi arandomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome
AT dhamijapuneet arandomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome
AT kumarniraj arandomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome
AT madhawgovind randomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome
AT guptaravi randomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome
AT dhamijapuneet randomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome
AT kumarniraj randomizedopenlabelexploratorytrialcomparingefficacyofamantadineandropiniroleinrestlesslegssyndrome